Assessment of response to induction therapy and its influence on 5-year failure-free survival (FFS) in Group III rhabdomyosarcoma (RMS): Intergroup Rhabdomyosarcoma Study (IRS)-IV experience
Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 8513-8513
Prognostic significance of residual mass at the end of therapy in Group III rhabdomyosarcoma (RMS): Intergroup Rhabdomyosarcoma Study (IRS) IV experience
Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 8501-8501